



# UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ

## Facultad de Ciencias Químicas



### Lab. General Microbiology

Case report: Meningitis caused by *Pseudomonas aeruginosa*



Created by: Ma. Dolores Pacheco Castillo  
Maestra: Tovar Oviedo Juana  
Grupo: 8:00-9:00

# Objective

Associate the knowledge on biochemical test for the identification of microorganism with the clinical importance for diagnosis and treatment in the patient.

To know the methods of identification and the specific antibiotic susceptibility of *Pseudomonas aeruginosa*.

# *Introduction*

- *Pseudomonas aeruginosa* is a non-fermentative gram negative bacillus.
- Characterized by the production of pyocyanin.
- Infection caused by this bacterium have characteristics such as exudation of bluish purulent content and grape-like odor for the production of pyocyanin.
- It prevails in patients with burns, cystic fibrosis, leukemia, organ transplants and intravenous drug use.



*P.Aeruginosa* at the microscopy  
(gramnegative bacillus).  
[www.textbookofbacteriology.net](http://www.textbookofbacteriology.net)

# Clinical Case



Craneal magnetic resonance image showing edematous bulb-mesencephalic disease.  
[portalesmedicos.com](http://portalesmedicos.com)

Male patient with 54 years old, entered at emergency service, reporting vomiting, high fever and neck stiffness with 48 hours of evolution. Lumbar puncture is performed and cerebrospinal fluid of turbid aspect with polymorphous predominance is obtained, with presence of (25mg/dL) glucose. The sample is sent to the laboratory for acute bacterial respiratory infections for culturing isolation and study of antibiotic susceptibility.

# Metodology

It make a cultive of the sample and it isolated Pseudomona aeruginosa and applying biochemical test: **oxidase** (42°C).



It has been made a test OF (oxid-fementation).

P. aeruginosa in blood agar  
(Koneman diagnóstico microbiológico:  
2008)

It was determinated the sensibility of the strain by the method of disk diffusion .

Clinical case

\*Ciprofloxacin  
\*Ceftriaxone  
\*Imipenem

\*Amikacin  
\*Piperacilin  
\*Aztreonam

Microbiology lab.

\*Ciprofloxacin      \*Ampicilin  
\*Ceftriaxone      \* Acid nalidixic  
\*Trimethoprim/sulphametoxasol

# Cytochrome Oxidase Test

Identification of:  
Pseudomonas,  
Campylobacter and  
Pasteurella.

## Method

- \*Take part of the sample and put in a strip filter paper.
- \*Add 2 to 3 drops of reagent.



## Results

Blue coloration after  
10 sec.

Cytochrome oxidase test, blue color  
Indicate cytochrome oxidase activity.  
(Koneman diagnóstico microbiológico:  
2008)

# OF (Oxide-Fermentation)

For microorganism which  
degrade glucose through  
fermentation and oxidation.

## Components:

- peptone 0.2%
- carbohydrate 1.0%
- agar (semisolid medium)

Open tube	Covered tube	Metabolism
Acid (yellow)	Alkaline (green)	Oxidative
Acid (yellow)	Acid (yellow)	Fermentative
Alkaline (green or blue)	Alkaline (green or blue)	---



## OF test:

**Oxidative reaction characterized by yellow color in the open tube, the green color in the tube 2 remains.** ([www.textbookofbacteriology.net](http://www.textbookofbacteriology.net))

# Results

Biochemical test	Clinical case	Microbiology laboratory
Oxidase	+	+
(OF)	+	+
Catalase	+	-----
SIM	-----	Movility (+) Production H2S (-) Production Indol (-)

**Clinical case**

susceptibility:  
 ceftriaxone  
 ciprofloxacin  
 imipenem  
 amikacin  
 piperacilin  
 aztreonam

**Resistance:**  
 carbenicillina  
 azocillin  
 gentamicin  
 ticarcillin

Microbiology Laboratory

susceptibility:  
 ceftriaxone  
 ciprofloxacin


Resistance:

- ✓ Trimethoprim/  
sulfamethoxazole
- ✓ Ampicilin
- ✓ Acid nalidixic

Picture 1: results obtained at the laboratory with results obtained in the clinical case.

Figure A) *Pseudomonas aeruginosa* antibiogram , using Ceftadizime (CAZ), Imipenem (IPM), meropenem (MEM), Ciprofloxacin (CIP) and Tobramicina (<http://aac.asm.org>)


Figura B) *P. aeruginosa* antibiogram using Ciprofloxacin (CIP), Ceftriaxone (CRO), Ampicilin (AM), Ácido nalidíxico(NA), Trimethoprim/ sulfamethoxasol (STX). Experimental results.



## CIPROFLOXACIN

**Mechanism:** inhibition of topoisomerase IV and bacterial DNA-gyrase. These topoisomerases alter DNA by introducing superhelical folds in double-stranded DNA, facilitating the unwinding of strands. Quinolones inhibit these subunits by preventing replication and transcription of bacterial DNA.

### Mecanismo de Acción ...



# Attachments

Table 1: Antimicrobial agents approved for testing and reporting on organisms by microbiology laboratories.

<i>Pseudomonas aeruginosa</i>		
Group A	<ul style="list-style-type: none"> <li>Ceftadizime</li> <li>Gentamicin</li> </ul>	<ul style="list-style-type: none"> <li>Tiobramicin</li> <li>piperacilin</li> </ul>
Group B	<ul style="list-style-type: none"> <li>Amikacin</li> <li>Aztreonam</li> <li>Cefepime</li> <li>Ciprofloxacin</li> <li>Levofloxacin</li> </ul>	<ul style="list-style-type: none"> <li>Imipenem</li> <li>Meropenem</li> <li>Doripenem</li> <li>Piperacilin-tazobactam</li> </ul>

Table 2. Intrinsic Resistance

Organism \ Antimicrobial Agent	Ampicillin/Ampoxicillin	Piperacilin	Ticarcilin	Ampicillin / sulbactam	Amoxicillina / clavulanate	Piperacilin / tazobactam	Cefotaxime	Ceftriaxone	Ceftadizime	Cefepime	Aztreonam	Imipenem	Meropenem	Ertapenem	Polymyxin B colistin	Aminoglycosides	Tetracyclines/Trigecycline	Trimethoprim	Trimethoprim/sulfametoxyazole	Cloranphenicol	Fosfomycin
Organism																					
Pseudomonas aeruginosa	R			R	R		R	R						R			R	R	R	R	R

## CONCLUSION

This results shown in the clinical case have completely coincided whit those obtained in the laboratory, which helps to verify that the procediments mentioned in the bibliography have been correctly performed.

Biochemical test for the identification of microorganisms as well as antimicrobial susceptibility test are of great clinical importance, as they allow the identification of the microorganism that causes the pathologies, as well as the selection of the apropiate antibiotic according to its capacity for bacterial inhibition an metabolism of the microorganism causing the disease.

# References

- ✉ \*Farías Cisneros E, Medina Campos R, Chavarría Garcés J. Neumonía nosocomial por Pseudomonas aeruginosa. Med. Int. Vol. 21 (n°5). Mex; 2005 (acceso 10 de marzo de 2017). Disponible en:  
*new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=6915*
- ✉ \**Clinical and Laboratory Standards Institute.* M100 Performance Standards for Antimicrobial susceptibility Testing; Twenty-Fifth Informational Supplement. Vol. 35. N°3: 2015(acceso 10 de marzo de 2017). Disponible en: Tzaloa.uaslp.mx
- ✉ \*Koneman W, Procop W, Schreckenberger P, Woods L, Janda W, Allen S, et al. Diagnóstico microbiológico. Ed. Médica Panamericana 6° edición. Buenos aires: 2008. Capítulo 7: bacilos gramnegativos no fermentadores pp 301-305. Protocolo 1.2, 1.5, 7.1. págs 1383-1401.